SUPERNUS PHARMACEUTICALS, INC. (SUPN) Form 8-K — Nov 2, 2026

Supernus Pharmaceuticals completed its merger on November 2, 2026 and notified Nasdaq to suspend trading of its common stock effective prior to the open that day. The company requested Nasdaq file a Form 25 to delist the stock from Nasdaq and deregister it under Section 12(b), and intends to subsequently file a Form 15 to deregister under Section 12(g) and suspend its SEC reporting obligations.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.